Adverum Biotechnologies, Inc. (ADVM) has been actively advancing its gene therapy pipeline, particularly with its lead candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022), for wet age-related macular degeneration (wet AMD).

**Financial and Corporate Updates:**

*   Adverum reported its second-quarter 2025 financial results on August 12, 2025, with an earnings per share (EPS) of ($2.34), missing the analysts' consensus estimate of ($2.24) by $0.10.
*   For the third quarter of 2025, analysts at HC Wainwright raised their EPS estimates for Adverum Biotechnologies to ($0.84) per share from a prior forecast of ($1.19) on August 13, 2025.
*   The company is estimated to report its third-quarter 2025 earnings on November 3, 2025.
*   As of September 30, 2024, Adverum held $153.2 million in cash, cash equivalents, and short-term investments, which is projected to fund operations into late 2025.
*   On August 12, 2025, Adverum announced the closure of a $10 million private placement with Frazier Life Sciences.
*   Jason Mitchell was appointed as Chief Commercial Officer, as reported on November 4, 2024.
*   In June 2025, Ozden Rabia Gurses, Adverum's Chief Medical Officer, received revised stock options.

**Clinical Pipeline Progress (Ixo-vec for Wet AMD):**

*   Adverum initiated the ARTEMIS Phase 3 study in February/March 2025. This pivotal trial evaluates the efficacy and safety of a one-time intravitreal (IVT) injection of Ixo-vec for wet AMD, comparing it to aflibercept. The ARTEMIS trial's enrollment has exceeded initial expectations.
*   Enrollment for the ARTEMIS Phase 3 trial is anticipated to be completed in the first quarter of 2026, with topline data expected in the first half of 2027.
*   Adverum plans to initiate AQUARIUS, the second Phase 3 trial for Ixo-vec in wet AMD, in the fourth quarter of 2025, subject to additional funding.
*   The LUNA Phase 2 study has provided positive interim results. On July 17, 2024, Adverum announced positive findings from the 26-week interim analysis of the LUNA Phase 2 trial, indicating that 76% of patients receiving the 6E10 dose were free from additional injections while maintaining stable visual acuity.
*   The company anticipates presenting the 9-month landmark analysis of the LUNA study and a pivotal Phase 3 trial design update in the fourth quarter of 2024.
*   Two-year follow-up data from the LUNA Phase 2 study are expected to be presented in the fourth quarter of 2025.

**Regulatory Designations:**

*   Ixo-vec received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) in August 2024.
*   Ixo-vec has also been granted PRIME designation from the European Medicines Agency (EMA) and an Innovation Passport from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of wet AMD.